

Novel Methods for the Facile Construction of 3,3-Disubstituted and 3,3-Spiro-2*H*,4*H*-benzo[*e*]1,2-thiazine-1,1-diones: Synthesis of (11*S*,12*R*,14*R*)-2-Fluoro-14-methyl-11-(methylethyl)spiro[4*H*-benzo[*e*]1,2-thiazine-3,2'-cyclohexane]-1,1-dione, an Agent for the Electrophilic Asymmetric Fluorination of Aryl Ketone Enolates

Zhaopeng Liu, Norio Shibata, and Yoshio Takeuchi*

Faculty of Pharmaceutical Sciences, Toyama Medical and Pharmaceutical University, Sugitani 2630, Toyama 930-0194, Japan

takeuchi@ms.toyama-mpu.ac.jp

Received June 26, 2000

Novel methods for the facile construction of 3,3-disubstituted and 3,3-spiro 2*H*,4*H*-benzo[*e*][1,2]-thiazine-1,1-diones **8a–h** are described. *o*-Methyl lithiation of *N*-Boc-*o*-toluenesulfonamide **6** followed by reaction with a variety of ketones gave the corresponding carbinol sulfonamides **7a–g**, which underwent cyclization under acidic (methanesulfonic acid) or neutral (NaI/TMSCI/MeCN) conditions to afford the sultams **8a–h** in high yields. The chiral spiro sultams **8g,h** were subjected to FClO₃ fluorination to give the *N*-fluorosultams **11a,b**, respectively, which were tested for electrophilic asymmetric fluorination of aryl ketone enolates. As a result, the *N*-fluorosultam **11a** exhibited modest asymmetric inducing abilities with the highest ee, reaching 70% for enantioselective fluorination of the lithium enolate of 2-methyl-1-tetralone.

Introduction

The sulfonamide antibiotics hold the prestigious position of being the first synthetic compounds to have had general utility in human therapy.¹ These exciting developments spawned considerable interest in their use in veterinary practice and in the preparation of many hundreds of cyclic variants (i.e., sultams).² In recent years, sultam templates have also become one of the synthetic strategies for the development of novel electrophilic fluorinating agents. Representative examples include nonracemic *N*-fluoro-2,10-camphorsultams **1**³ and **2**⁴ and saccharin-based electrophilic fluorinating agents **3**⁵ and **4**⁶ (Figure 1). Recently, we reported a novel method for the synthesis of 3-monosubstituted 2*H*,3*H*,4*H*-benzo[*e*]1,2-thiazine-1,1-diones using *orthomethyl lithiation-cyclization* of *N*-acyl-*o*-toluenesulfonamides and proved that the *N*-fluorosultam **5** had some ability for the electrophilic fluorination of aryl ketone enolates.⁷ As a part of our continuing research on the development of highly efficient enantioselective fluorinating agents,⁸ we were interested in the 3,3-disubstituted 2*H*,4*H*-benzo[*e*]1,2-thiazine-1,1-diones, especially those with a spiro




Figure 1.

structure at the 3 position. In this paper, we report novel methods for the construction of these kinds of sultams that led to the synthesis of (11*S*,12*R*,14*R*)-2-fluoro-14-methyl-11-(methylethyl)-spiro[4*H*-benzo[*e*]1,2-thiazine-3,2'-cyclohexane]-1,1-dione, an agent for the electrophilic asymmetric fluorination of aryl ketone.

Results and Discussion

It is well documented that *N*-substituted *o*-toluenesulfonamides undergo metalation at the methyl group as well as the nitrogen atom.^{7,9} Therefore, it is reasonable to expect that a properly *N*-protected *o*-toluenesulfonamide will react with ketones after *o*-methyl lithiation to generate tertiary alcohols, which might undergo cyclization to form our target compounds. However, there is only one reported example of *N*-methyl- or *N*-phenyl-substituted *o*-toluenesulfonamides which, when treated with excess butyllithium and reacted with benzophenone, gave carbinol sulfonamides. These were not very stable and

* To whom correspondence should be addressed. Phone: +81 76 434 7555. Fax: +81 76 434 5053.

(1) Bowman, W. C.; Rand, M. J. *Textbook of Pharmacology*, 2nd ed.; Blackwell: London, 1979; Chapter 34.

(2) Katritzky, A. R.; Rees, C. W.; Scriven, E. F. V. *Comprehensive Heterocyclic Chemistry II*; Elsevier: Oxford, 1996; Vols. 3 and 4.

(3) Differding, E.; Lang, R. W. *Tetrahedron Lett.* **1988**, *29*, 6087–6090.

(4) (a) Davis, F. A.; Han, W. *Tetrahedron Lett.* **1991**, *32*, 1631–1634. (b) Davis, F. A.; Zhou, P.; Murphy, C. K.; Sundarababu, G.; Qi, H.; Han, W.; Przeslawski, R. M.; Chen, B.-C.; Carroll, P. J. *J. Org. Chem.* **1998**, *63*, 2273–2280.

(5) (a) Differding, E.; Lang, R. W. *Helv. Chim. Acta* **1989**, *72*, 1248–1252. (b) Differding, E.; Rüegg, G. W.; Lang, R. W. *Tetrahedron Lett.* **1991**, *32*, 1779–1782.

(6) Takeuchi, Y.; Suzuki, T.; Satoh, A.; Shiragami, T.; Shibata, N. *J. Org. Chem.* **1999**, *64*, 5708–5711.

(7) Takeuchi, Y.; Liu, Z.; Satoh, A.; Shiragami, T.; Shibata, N. *Chem. Pharm. Bull.* **1999**, *47*, 1730–1733.

(8) (a) Davis, F. A.; Qi, H.; Sundarababu, G. In *Enantiocontrolled Synthesis of Fluoro-organic Compounds*; Soloshonok, V. A., Ed.; John Wiley & Sons, Ltd: Chichester, 1999; pp 1–32. (b) Bravo, P.; Resnati, G. *Tetrahedron: Asymmetry* **1990**, *1*, 661–692.

(9) (a) Watanabe, H.; Hauser, C. R. *J. Org. Chem.* **1968**, *33*, 4278–4279. (b) Watanabe, H.; Mao, C.-L.; Barnish, I. T.; Hauser, C. R. *J. Org. Chem.* **1969**, *33*, 919–924. (c) Takahashi, M.; Ohtsuki, K.; Taga, T.; Chohann, Y. *Heterocycles* **1998**, *48*, 1643–1648. (d) Snieckus, V. *Chem. Rev.* **1990**, *90*, 879–933. (e) Narashimhan, N. S.; Mali, R. S. *Synthesis* **1983**, 957–986.

Table 1. Formation of the Carbinol Sulfonamides **7a–g** via *o*-Methyl Lithiation of **6** Followed by Reaction with Ketones

entry	ketone	product	yield (%)
1			77
2			94
3			96
4			85
5			84
6			75
7			95

underwent thermal dehydration to afford unsaturated sulfonamides.^{9a} Considering that the *N*-protective group should be easily removable, and inspired by the reports that *N*-Boc-*p*-toluenesulfonamide had shown significant utility as a Mitsunobu *N*-nucleophile,¹⁰ we chose the readily available *N*-Boc-*o*-toluenesulfonamide **6** as our starting material. In fact, when **6** was treated with 2 equiv of BuLi at $-78\text{ }^{\circ}\text{C}$, *o*-methyl lithiation occurred rapidly. The resulting anion reacted with a variety of ketones to give the corresponding carbinol sulfonamides **7a–g** in good yields (Table 1). In the case of *l*-menthone, only one isomer **7g** was isolated. The diastereoselectivity is probably due to the predominant preference for the equatorial attack of the hindered carbanion toward the menthone carbonyl. Thus, the *S* configuration is assumed for the newly created stereocenter of **7g**.

To obtain the sultam structure, we first examined the intramolecular cyclization of the carbinol sulfonamides **7** under Mitsunobu reaction conditions.^{10a,11} However, this approach did not work at all, possibly owing to the bulkiness of the various tertiary alcohol groups. We then investigated the cyclization of **7a–f** under acidic conditions and found that methanesulfonic acid was effective and the corresponding sultams **8a–f** were obtained in high yields (Table 2, method A).


(10) (a) Henry, J. R.; Marcin, L. R.; McIntosh, M. C.; Scola, P. M.; Harris, G. D.; Weinreb, S. M. *Tetrahedron Lett.* **1989**, 30, 5709–5712. (b) Degerbeck, F.; Fransson, B.; Grehn, L.; Ragnarsson, U. *J. Chem. Soc., Perkin Trans 1* **1992**, 245–253. (c) Campbell, J. A.; David, J. H. *J. Org. Chem.* **1993**, 58, 2900–2903. (d) O'Brien, P.; Towers, T. D.; Voith, M. *Tetrahedron Lett.* **1998**, 39, 8175–8178.

(11) For a review, see: Mitsunobu, O. *Synthesis* **1981**, 1–28.

Table 2. Formation of the Sultams **8a–g** by Cyclization of the Sulfonamides **7**


entry	sulfonamide 7	sultam 8	yield (%)	
			A ^a	B ^b
1	7a		94	96
2	7b		90	93
3	7c		92	99
4	7d		89	94
5	7e		90	95
6	7f		93	98
7	7g		35 ^d	91 ^e

^a Method A: MeSO₃H, CH₂Cl₂, rt, 24 h. ^b Method B: TMSCl, NaI, MeCN, reflux, 1 h. ^c **8g**: (11*S*,12*R*,14*R*)-isomer. **8h**: (11*S*,12*S*,14*R*)-isomer. ^d **8g**:**8h** = 1:2.5. ^e **8g**:**8h** = 5.5:1.

Scheme 1

A sequence of the consecutive *N*-deprotective cyclization process under acidic conditions is shown in Scheme 1, with the substrate **7b** as an example. When a solution of **7b** in CH₂Cl₂ was treated with 3 equiv of methanesulfonic acid at room temperature, dehydration occurred rapidly to form the unsaturated sulfonamide **9**, which slowly deprotected to give **10**. The intermediate **10** appears to undergo an acid-catalyzed addition process to produce the sultam **8b**. Both intermediates, **9** and **10**, could be isolated, and their structures were confirmed by spectral studies.

However, when this procedure was applied to **7g**, a mixture of two separable diastereomers, **8g** and **8h**, was obtained in only 35% yield, with a ratio of 1:2.5 (Table 2, entry 7, method A). The stereochemistry of the newly created spiro carbon was confirmed by X-ray crystal-



lographic analysis of a crystalline descendant **11a**. The low yield in the case of **7g** may be due to steric hindrance by the neighboring isopropyl group in the cyclohexane ring and/or the rearrangement of the putative carbocation thus formed. Since the enantiopure sultams **8g,h** might be good templates for developing new electrophilic asymmetric fluorinating agents, we examined the reaction conditions for this cyclization.

When the TMSCl/NaI/MeCN/reflux system was employed, the cyclization went smoothly to produce the sultams **8g,h** in 91% yield, with a ratio of 5.5:1 (Table 2, entry 7, method B). The reversed ratio of **8g** and **8h** can be explained from the mechanistic considerations. As shown in Scheme 1, partial racemization might occur in this acid-mediated cyclization process (Scheme 1), and the major product **8h** retains the *S* configuration of **7g** at the newly formed spiro carbon. In contrast, the TMSCl/NaI/MeCN mediated cyclization (method B) might proceed mainly via an $\text{S}_{\text{N}}2$ process, therefore the major products **8g** should have the reversed configuration of **7g**. The confirmed *R* configuration of the spiro carbon of **8g** also supports the assumed *S* configuration of **7g**.

The TMSCl/NaI/MeCN system is well-known as a versatile reagent for reaction with many functional groups.¹² As far as we know, this is the first report of its use to effect a cyclization. In the same way, sultams **8a–f** were also obtained in almost quantitative yields (Table 2, method B). Finally, both **8g** and **8h** were separately treated with FCIO_3 ¹³ in the presence of NaH in THF to give the corresponding diastereomerically pure *N*-fluoro sultams **11a** [(1*S*,12*R*,14*R*)-isomer] and **11b** [(1*S*,12*S*,14*R*)-isomer] in 81% and 44% yields, respectively (Scheme 2).

Asymmetric enolate fluorinations were typically carried out at $-50\text{ }^\circ\text{C}$ by adding 1.2 equiv of **11a** or **11b** to the preformed enolates generated by treatment of 1.5 equiv of LHMDS with the corresponding ketones. The results are summarized in Table 3. For comparing the asymmetric inducing abilities of **11a** or **11b**, 2-methylindanone and 2-benzylindanone were tested as substrates. In both cases, **11a** gave much better ee's than **11b** (Table 3, entries 1–4). The highest asymmetric induction was observed for the fluorination of 2-methyl-1-tetralone with **11a**, affording the 2-fluoro-2-methyl-1-tetralone (**12e**) in 65% yield with an ee of 70%.

In summary, we have developed two novel methods for the preparation of 3,3-disubstituted and 3,3-spiro-2*H*,4*H*-benzo[*e*]1,2-thiazine-1,1-diones. The TMSCl/NaI/MeCN reagent system (method B) was used for the first time to cause a cyclization. This system gave better results than the method using methanesulfonic acid (method A). The success of this new method led us to synthesize (1*S*,

Table 3. Asymmetric Fluorination of Aryl Ketone Enolates Using *N*-Fluorosultams **11**

entry	<i>N</i> -F Sultam	Products	R	ee (%)	config.	isolated yield (%)	
1	11a		Me	12a	40 ^a	<i>S</i> ^d	76
2	11b		Me	12b	13 ^a	<i>R</i>	69
3	11a		Bn	12c	54 ^a	<i>S</i>	59
4	11b		Bn	12d	24 ^a	<i>R</i>	42
5	11a		<i>p</i> -OMe-Bn	12e	51 ^b	ND ^e	52

6	11a			12f	33 ^c	ND ^e	61

7	11a		Me	12g	70 ^a	<i>S</i>	65
8	11a		Bn	12h	56 ^b	<i>S</i>	61

^a Chiral OB column (10% *i*-PrOH/hexane). ^b Chiral OJ column (10% *i*-PrOH/hexane). ^c Chiral OJ column (EtOH). ^d References 4 and 6. ^e ND: not determined.

12*R*,14*R*)-2-fluoro-14-methyl-11-(methylethyl)-spiro[4*H*-benzo[*e*]-1,2-thiazine-3,2'-cyclohexane]-1,1-dione (**11a**) for the electrophilic asymmetric fluorination of aryl ketone enolates. This agent exhibited modest asymmetric inducing abilities with the highest ee obtained being 70%. This is comparable to Differding's (**1**) and Davis's (**2**) agents.

Experimental Section

General Methods. Melting points were determined on a micro-melting point apparatus and are uncorrected. IR spectra (cm^{-1}) were recorded on a 1600 FT-IR spectrometer. ¹H NMR (270 MHz) and ¹³C NMR spectra (75.5 MHz) were recorded at room temperature for CDCl_3 solutions, unless otherwise stated. All chemical shifts are reported as δ values (ppm) relative to Me_4Si (0.00 ppm) and CDCl_3 (77.0 ppm) as internal standards for ¹H and ¹³C NMR spectra, respectively. ¹⁹F NMR spectra were measured with CFCl_3 as an internal standard and were taken with a 254 MHz spectrometer. Upfield shifts are quoted as negative δ values. Mass spectra were obtained by EI method. Column chromatography and preparative TLC were performed on BW-200 (Fuji Silysia) and Kieselgel 60 F-254 plates, respectively. All reactions involving oxygen- or moisture-sensitive compounds were carried out under a dry N_2 atmosphere. Unless otherwise noted, reagents were added by syringe. THF was distilled from sodium/benzophenone immediately prior to use.

Preparation of *N*-Boc-*o*-toluenesulfonamide **6.**¹⁴ *o*-Toluenesulfonamide (8.55 g, 50 mmol) was suspended in CH_2Cl_2 (60 mL) containing Et_3N (7.65 mL, 55 mmol) and DMAP (610 mg, 5 mmol). A solution of di-*tert*-butyl dicarbonate (12.5 g, 57.5 mmol) in CH_2Cl_2 (100 mL) was added dropwise with stirring over 10 min. After 4 h, the solution was concentrated in vacuo and the residue treated with EtOAc (300 mL) and 1 N HCl (200 mL). The EtOAc layer was washed successively with water and brine, dried (MgSO_4), and concentrated. Crystallization from hexane provided **6** as a white solid (12.57 g, 93%): mp 109–110 $^\circ\text{C}$; IR (KBr) 3240, 1741, 1710, 1346, 1154, 758 cm^{-1} ; ¹H NMR δ 1.34 (s, 9H), 2.67 (s, 3H), 7.35 (m, 2H), 7.44 (br s, 1H), 7.53 (td, $J = 7.6, 1.5$ Hz, 1H), 8.12 (dd, $J = 7.6, 1.5$ Hz, 1H); ¹³C NMR δ 20.4, 28.0, 84.5, 126.1, 131.2, 132.5, 133.8, 136.9, 137.5, 149.7; MS m/z 271 (M^+), 256 ($\text{M}^+ - \text{Me}$); HRMS calcd for $\text{C}_{12}\text{H}_{17}\text{NO}_4\text{S}$ 271.0878, found 271.0902. Anal. Calcd for $\text{C}_{12}\text{H}_{17}\text{NO}_4\text{S}$: C, 53.12; H, 6.32; N, 5.16. Found: C, 53.23; H, 6.39; N, 5.13.

(12) For a review, see: Olah, G. A.; Narang, S. C. *Tetrahedron* **1982**, *38*, 2225–2277.

(13) (a) Takeuchi, Y.; Nagata, K.; Koizume, T. *J. Org. Chem.* **1987**, *52*, 5061–5063. (b) Takeuchi, Y.; Nagata, K.; Koizume, T. *J. Org. Chem.* **1989**, *54*, 5453–5459. See also *J. Org. Chem.* **1988**, *53*, 4160.

(14) Neustadt, B. R. *Tetrahedron Lett.* **1994**, *35*, 379–380.

General Procedure for the Preparation of Carbinol Sulfonamides 7a–g. To a stirred solution of *N*-Boc *o*-toluene-sulfonamide (1.09 g, 4 mmol) in THF (20 mL) was added a 1.53 M solution of BuLi in hexane (5.22 mL, 4 mmol) under nitrogen at $-78\text{ }^{\circ}\text{C}$. The reaction mixture was stirred for 10 min and a solution of ketone (4 mmol) in 4 mL THF was added. After 1 h, saturated aqueous NH_4Cl was added. The mixture was extracted with EtOAc, the combined organic layers were washed with brine, dried (MgSO_4) and concentrated in vacuo. The residue was chromatographed (30% EtOAc in hexane) to give the carbinol sulfonamide 7 (Table 1).

7a: colorless oil; IR (neat) 3502, 3227, 1740, 1342, 1148, 758 cm^{-1} ; $^1\text{H NMR}$ δ 1.31 (s, 6H), 1.35 (s, 9H), 3.30 (s, 2H), 7.42 (d, $J = 7.3$ Hz, 2H), 7.57 (td, $J = 7.3, 1.5$ Hz, 1H), 8.17 (m, 2H); $^{13}\text{C NMR}$ δ 28.1, 30.5, 45.2, 71.8, 84.2, 126.8, 131.5, 133.2, 133.9, 137.8, 138.2, 149.9; MS m/z 273 ($\text{M}^+ + \text{H} - t\text{-Bu}$); HRMS calcd for $\text{C}_{11}\text{H}_{15}\text{NO}_5\text{S}$ ($\text{M}^+ + \text{H} - t\text{-Bu}$) 273.0671, found 273.0663. Anal. Calcd for $\text{C}_{15}\text{H}_{23}\text{NO}_5\text{S}$: C, 54.69; H, 7.04; N, 4.25. Found: C, 54.54; H, 7.16; N, 4.19.

7b: colorless glass; IR (CHCl_3) 3420, 1732, 1339, 1161, 758 cm^{-1} ; $^1\text{H NMR}$ δ 0.95 (s, 3H), 1.01 (s, 9H), 1.29 (s, 9H), 2.11 (s, 1H), 2.93, 3.68 (ABq, $J = 14.2$ Hz, 2H), 7.34 (m, 2H), 7.47 (m, 1H), 8.09 (s, 1H), 8.13 (d, $J = 7.8$ Hz, 1H); $^{13}\text{C NMR}$ δ 21.5, 25.7, 28.1, 38.6, 39.2, 78.0, 84.1, 126.6, 131.4, 132.9, 134.7, 138.6, 138.7, 149.3; MS m/z 371 (M^+), 315 ($\text{M}^+ + \text{H} - t\text{-Bu}$); HRMS calcd for $\text{C}_{18}\text{H}_{29}\text{NO}_5\text{S}$ 371.1766, found 371.1763. Anal. Calcd for $\text{C}_{18}\text{H}_{29}\text{NO}_5\text{S}$: C, 58.20; H, 7.87; N, 3.77. Found: C, 58.17; H, 7.89; N, 3.59.

7c: colorless glasses; IR (CHCl_3) 3679, 3381, 1741, 1343, 1216, 757 cm^{-1} ; $^1\text{H NMR}$ δ 1.34 (s, 9H), 1.64 (s, 3H), 3.12 (br s, 1H), 3.38, 3.69 (ABq, $J = 14.1$ Hz, 2H), 6.85 (m, 1H), 7.21–7.42 (m, 7H), 7.84 (br s, 1H), 8.13 (m, 1H). Anal. Calcd for $\text{C}_{20}\text{H}_{25}\text{NO}_5\text{S}$: C, 61.36; H, 6.44; N, 3.58. Found: C, 61.37; H, 6.51; N, 3.49.

7d: colorless glasses; IR (CHCl_3) 3361, 1725, 1309, 1216, 758 cm^{-1} ; $^1\text{H NMR}$ δ 1.34 (s, 9H), 3.50, 4.15 (ABq, $J = 14.1$ Hz, 2H), 4.83 (s, 1H), 6.40 (d, $J = 7.8$ Hz, 1H), 7.19 (td, $J = 7.6, 1.5$ Hz, 1H), 7.31–7.39 (m, 4H), 7.53 (m, 2H), 7.64 (br s, 1H), 8.12 (dd, $J = 7.6, 1.5$ Hz, 1H); $^{19}\text{F NMR}$ δ -74.9 (s). Anal. Calcd for $\text{C}_{20}\text{H}_{22}\text{F}_3\text{NO}_5\text{S}$: C, 53.93; H, 4.98; N, 3.14. Found: C, 53.85; H, 4.78; N, 3.06.

7e: colorless oil; IR (neat) 3506, 3219, 1739, 1341, 1149, 758 cm^{-1} ; $^1\text{H NMR}$ δ 1.35 (s, 9H), 1.48–1.68 (m, 10H), 2.44 (br s, 1H), 3.27 (s, 2H), 7.40 (t, $J = 7.6$ Hz, 1H), 7.52 (t, $J = 7.6$ Hz, 1H), 8.16 (d, $J = 7.8$ Hz, 1H), 8.44 (s, 1H); $^{13}\text{C NMR}$ δ 22.3, 25.9, 28.1, 31.2, 38.4, 72.3, 84.1, 126.7, 131.5, 133.0, 133.9, 137.4, 138.2, 149.3. Anal. Calcd for $\text{C}_{18}\text{H}_{27}\text{NO}_5\text{S}$: C, 58.51; H, 7.37; N, 3.79. Found: C, 58.65; H, 7.46; N, 3.62.

7f: colorless oil; IR (neat) 3487, 3222, 1739, 1345, 1150, 759 cm^{-1} ; $^1\text{H NMR}$ δ 1.36 (s, 9H), 2.06 (m, 1H), 2.44 (ddd, $J = 11.2, 7.6, 3.9$ Hz, 1H), 2.81–3.20 (m, 2H), 2.93 (br s, 1H), 3.52, 3.69 (ABq, $J = 14.2$ Hz, 2H), 7.03–7.18 (m, 3H), 7.25–7.27 (m, 3H), 7.38–7.48 (m, 2H), 8.20 (dd, $J = 7.6, 1.8$ Hz, 1H); $^{13}\text{C NMR}$ δ 28.1, 29.6, 41.3, 41.8, 84.1, 84.4, 123.5, 125.1, 126.6, 126.9, 128.6, 131.4, 133.0, 134.0, 137.2, 138.3, 142.6, 147.0, 149.3. Anal. Calcd for $\text{C}_{21}\text{H}_{25}\text{NO}_5\text{S}$: C, 62.51; H, 6.25; N, 3.47. Found: C, 62.61; H, 6.28; N, 3.43.

7g: colorless glass; $[\alpha]_D^{25} + 26.7$ (c 0.99, CHCl_3); IR (CHCl_3) 3528, 3214, 1742, 1344, 1150, 758 cm^{-1} ; $^1\text{H NMR}$ δ 0.78 (d, $J = 6.3$ Hz, 3H), 0.99 (d, $J = 7.1$ Hz, 6H), 1.36 (s, 9H), 1.16–1.80 (m, 8H), 2.24 (br s, 1H), 2.37 (m, 1H), 2.76, 4.15 (ABq, $J = 14.2$ Hz, 2H), 7.40 (t, $J = 7.3$ Hz, 2H), 7.53 (t, $J = 7.6$ Hz, 1H), 8.19 (d, $J = 7.6$ Hz, 1H), 8.68 (s, 1H); $^{13}\text{C NMR}$ δ 18.5, 21.3, 22.7, 24.2, 25.9, 28.1, 35.1, 43.8, 46.5, 52.4, 76.3, 83.7, 126.7, 131.4, 132.8, 134.8, 137.8, 138.3, 149.4. Anal. Calcd for $\text{C}_{22}\text{H}_{35}\text{NO}_5\text{S}$: C, 62.09; H, 8.29; N, 3.29. Found: C, 61.96; H, 8.50; N, 3.18.

General Procedure for the Preparation of Sultams 8a–g. Method A. Methanesulfonic acid (0.39 mL, 6 mmol) was added to a stirred solution of 7 (2 mmol) in CH_2Cl_2 (10 mL) at room temperature. The reaction mixture was stirred for 24 h. CH_2Cl_2 (20 mL) was added, and the organic layer was washed with water, brine, dried (MgSO_4), and concentrated in vacuo. The residue was chromatographed (30% EtOAc in hexane) to give sultam 8 (Table 2).

Method B. To a stirred solution of 7 (2 mmol) in MeCN (10 mL) was added under nitrogen sodium iodide (0.93 g, 6.2 mmol) and chlorotrimethylsilane (0.76 mL, 6 mmol). The reaction mixture was refluxed for 1 h. It was cooled to room temperature, and 10% sodium thiosulfate aqueous solution was added. The mixture was extracted with EtOAc, and the combined organic layers were washed with water, brine, dried (MgSO_4), and concentrated in vacuo. The residue was chromatographed (30% EtOAc in hexane) to give sultam 8 (Table 2).

3,3-Dimethyl-2*H*,4*H*-benzo[*e*][1,2]thiazine 1,1-dione (8a): colorless oil; IR (neat) 3262, 1318, 1216, 758 cm^{-1} ; $^1\text{H NMR}$ δ 1.36 (s, 6H), 3.02 (s, 2H), 4.23 (s, 1H), 7.27 (d, $J = 7.3$ Hz, 1H), 7.41 (td, $J = 7.6, 1.5$ Hz, 1H), 7.49 (td, $J = 7.6, 1.5$ Hz, 1H), 7.80 (dd, $J = 7.6, 1.5$ Hz, 1H); $^{13}\text{C NMR}$ δ 30.3, 40.5, 56.4, 123.1, 127.6, 129.6, 132.3, 135.3, 138.3; MS m/z 211 (M^+), 196 ($\text{M}^+ - \text{Me}$); HRMS calcd for $\text{C}_{10}\text{H}_{13}\text{NO}_2\text{S}$ 211.0667, found 211.0657. Anal. Calcd for $\text{C}_{10}\text{H}_{13}\text{NO}_2\text{S}$: C, 56.85; H, 6.20; N, 6.63. Found: C, 56.76; H, 6.34; N, 6.59.

3-*tert*-Butyl-3-methyl-2*H*,4*H*-benzo[*e*][1,2]thiazine 1,1-dione (8b): colorless prisms; mp 204–206 $^{\circ}\text{C}$; IR (KBr) 3257, 1312, 1216, 756 cm^{-1} ; $^1\text{H NMR}$ δ 1.04 (s, 3H), 1.07 (s, 9H), 2.70, 3.46 (ABq, $J = 14.9$ Hz, 2H), 3.88 (s, 1H), 7.31 (d, $J = 7.3$ Hz, 1H), 7.41 (td, $J = 7.3, 1.5$ Hz, 1H), 7.48 (td, $J = 7.3, 1.5$ Hz, 1H), 7.80 (dd, $J = 7.3, 1.5$ Hz, 1H); $^{13}\text{C NMR}$ δ 23.0, 25.7, 33.6, 38.0, 65.1, 122.3, 127.3, 130.0, 132.1, 136.5, 138.4; MS m/z 254 ($\text{M}^+ + 1$), 253 (M^+), 238 ($\text{M}^+ - \text{Me}$), 196 ($\text{M}^+ - t\text{-Bu}$); HRMS calcd for $\text{C}_{13}\text{H}_{19}\text{NO}_2\text{S}$ 253.1137, found 253.1129. Anal. Calcd for $\text{C}_{13}\text{H}_{19}\text{NO}_2\text{S}$: C, 61.63; H, 7.56; N, 5.53. Found: C, 61.77; H, 7.60; N, 5.48.

3-Methyl-3-phenyl-2*H*,4*H*-benzo[*e*][1,2]thiazine 1,1-dione (8c): colorless glass; IR (CHCl_3) 3267, 1318, 1169, 757 cm^{-1} ; $^1\text{H NMR}$ δ 1.58 (s, 3H), 3.22, 3.49 (ABq, $J = 15.1$ Hz, 2H), 4.50 (s, 1H), 7.29–7.58 (m, 8H), 7.85 (d, $J = 7.1$ Hz, 1H); $^{13}\text{C NMR}$ δ 29.4, 41.1, 61.5, 122.6, 125.2, 127.5, 127.7, 128.7, 129.6, 132.4, 135.1, 138.6, 145.9; MS m/z 274 ($\text{M}^+ + 1$), 273 (M^+), 258 ($\text{M}^+ - \text{Me}$); HRMS calcd for $\text{C}_{15}\text{H}_{15}\text{NO}_2\text{S}$ 273.0823, found 273.0815. Anal. Calcd for $\text{C}_{15}\text{H}_{15}\text{NO}_2\text{S}$: C, 65.91; H, 5.53; N, 5.12. Found: C, 65.89; H, 5.56; N, 5.09.

3-Phenyl-3-trifluoromethyl-2*H*,4*H*-benzo[*e*][1,2]thiazine 1,1-dione (8d): colorless prisms; mp 194–195 $^{\circ}\text{C}$; IR (KBr) 3377, 3255, 1316, 1216, 758 cm^{-1} ; $^1\text{H NMR}$ (CD_3OD) δ 3.80, 4.20 (ABq, $J = 14.9$ Hz, 2H), 6.74 (d, $J = 7.6$ Hz, 1H), 7.10 (t, $J = 7.6$ Hz, 1H), 7.25 (d, $J = 7.8$ Hz, 1H), 7.31–7.36 (m, 3H), 7.55 (m, 2H), 7.96 (d, $J = 7.8$ Hz, 1H); $^{19}\text{F NMR}$ δ -78.98 (s); $^{13}\text{C NMR}$ (CD_3OD) δ 37.7, 102.0, 127.8, 128.0, 128.3, 128.8, 129.1, 132.1, 133.4, 134.0, 138.0, 144.0; MS m/z 345 ($\text{M}^+ + \text{H}_2\text{O}$), 327 (M^+), 258 ($\text{M}^+ - \text{CF}_3$); HRMS calcd for $\text{C}_{15}\text{H}_{12}\text{F}_3\text{NO}_2\text{S}$ 327.0541, found 327.0552. Anal. Calcd for $\text{C}_{15}\text{H}_{12}\text{F}_3\text{NO}_2\text{S} \cdot \text{H}_2\text{O}$: C, 52.16; H, 4.09; N, 4.06. Found: C, 51.94; H, 4.26; N, 4.01.

Spiro(2*H*,4*H*-benzo[*e*][1,2]thiazine-3,1'-cyclohexane) 1,1-dione (8e): colorless prisms; mp 154–155 $^{\circ}\text{C}$; IR (KBr) 3258, 1323, 1216, 759 cm^{-1} ; $^1\text{H NMR}$ δ 1.32 (m, 1H), 1.42–1.82 (m, 9H), 3.01 (s, 2H), 4.13 (s, 1H), 7.36 (d, $J = 7.6$ Hz, 1H), 7.39 (td, $J = 7.6, 1.5$ Hz, 1H), 7.48 (td, $J = 7.6, 1.5$ Hz, 1H), 7.80 (dd, $J = 7.3, 1.5$ Hz, 1H); $^{13}\text{C NMR}$ δ 21.6, 25.4, 38.1, 40.0, 58.4, 123.1, 127.4, 129.7, 132.2, 135.0, 138.4; MS m/z 251 (M^+); HRMS calcd for $\text{C}_{13}\text{H}_{17}\text{NO}_2\text{S}$ 251.0980, found 251.0977. Anal. Calcd for $\text{C}_{13}\text{H}_{17}\text{NO}_2\text{S}$: C, 62.12; H, 6.82; N, 5.57. Found: C, 61.96; H, 6.91; N, 5.47.

Spiro(2*H*,4*H*-benzo[*e*][1,2]thiazine-3,1'-indane) 1,1-dione (8f): colorless needles; mp 124–126 $^{\circ}\text{C}$; IR (KBr) 3247, 1315, 1169, 757 cm^{-1} ; $^1\text{H NMR}$ δ 2.31 (m, 2H), 2.99 (m, 2H), 3.31 (s, 2H), 4.49 (s, 1H), 7.05 (d, $J = 7.6$ Hz, 1H), 7.15–7.32 (m, 4H), 7.48 (m, 2H), 7.88 (d, $J = 7.3$ Hz, 1H); $^{13}\text{C NMR}$ δ 29.5, 37.9, 41.1, 68.8, 122.8, 122.9, 125.2, 127.5, 127.6, 128.9, 129.4, 132.4, 135.4, 139.5, 142.2, 145.9; MS m/z 285 (M^+); HRMS calcd for $\text{C}_{16}\text{H}_{15}\text{NO}_2\text{S}$ 285.0823, found 285.0805. Anal. Calcd for $\text{C}_{16}\text{H}_{15}\text{NO}_2\text{S}$: C, 67.34; H, 5.30; N, 4.91. Found: C, 67.25; H, 5.38; N, 4.81.

(11*S*,12*R*,14*R*)-14-Methyl-11-(methylene)-spiro(2*H*,4*H*-benzo[*e*][1,2]thiazine-3,2'-cyclohexane) 1,1-dione (8g): colorless needles; mp 96 $^{\circ}\text{C}$; $[\alpha]_D^{28} - 44.7$ (c 1.22, CHCl_3); IR (KBr) 3288, 1316, 1169, 757 cm^{-1} ; $^1\text{H NMR}$ δ 0.82 (d, $J = 6.6$

Hz, 6H), 0.92 (d, $J = 7.1$ Hz, 3H), 0.81–1.00 (m, 2H), 1.14–1.35 (m, 2H), 1.59–1.82 (m, 4H), 2.62 (m, 1H), 2.65, 3.56 (ABq, $J = 15.3$ Hz, 2H), 4.12 (s, 1H), 7.29 (d, $J = 7.3$ Hz, 1H), 7.39 (t, $J = 7.3$ Hz, 1H), 7.49 (t, $J = 7.3$ Hz, 1H), 7.79 (d, $J = 7.3$ Hz, 1H); ^{13}C NMR δ 18.0, 22.1, 22.3, 24.7, 26.1, 28.0, 34.9, 38.6, 48.8, 51.7, 62.2, 122.5, 127.1, 129.5, 132.2, 136.4, 138.5; MS m/z 307 (M^+), 292 ($\text{M}^+ - \text{Me}$); HRMS calcd for $\text{C}_{17}\text{H}_{25}\text{NO}_2\text{S}$ 307.1606, found 307.1618. Anal. Calcd for $\text{C}_{17}\text{H}_{25}\text{NO}_2\text{S}$: C, 66.41; H, 8.20; N, 4.56. Found: C, 66.54; H, 8.40; N, 4.54.

(11*S*,12*S*,14*R*)-14-Methyl-11-(methylethyl)spiro(2*H*,4*H*-benzo[*e*][1,2]thiazine-3,2'-cyclohexane) 1,1-dione (8*h*): colorless needles; mp 145–147 °C; $[\alpha]_{\text{D}}^{25} -3.1$ (c 0.30, CHCl_3); IR (KBr) 3353, 3271, 1308, 1168, 758 cm^{-1} ; ^1H NMR δ 0.73–0.98 (m, 2H), 0.79 (d, $J = 6.3$ Hz, 3H), 0.86 (d, $J = 6.8$ Hz, 3H), 0.97 (d, $J = 7.0$ Hz, 3H), 1.25–1.45 (m, 2H), 1.50–1.84 (m, 4H), 2.45 (m, 1H), 2.97, 3.39 (ABq, $J = 14.9$ Hz, 2H), 3.85 (s, 1H), 7.28 (d, $J = 7.3$ Hz, 1H), 7.41 (t, $J = 7.3$ Hz, 1H), 7.48 (t, $J = 7.3$ Hz, 1H), 7.80 (d, $J = 7.3$ Hz, 1H); ^{13}C NMR δ 19.1, 22.4, 23.0, 24.7, 25.4, 29.6, 29.9, 35.0, 48.6, 52.6, 64.5, 122.4, 127.4, 129.4, 132.2, 135.6, 138.9; MS m/z 307 (M^+), 292 ($\text{M}^+ - \text{Me}$); HRMS calcd for $\text{C}_{17}\text{H}_{25}\text{NO}_2\text{S}$ 307.1606, found 307.1616. Anal. Calcd for $\text{C}_{17}\text{H}_{25}\text{NO}_2\text{S}$: C, 66.41; H, 8.20; N, 4.56. Found: C, 66.51; H, 8.27; N, 4.63.

Intermediates 9,10. Methanesulfonic acid (0.08 mL, 1.2 mmol) was added to a stirred solution of **7b** (148 mg, 0.4 mmol) in CH_2Cl_2 (4 mL) at room temperature. After stirring for 1 h, the reaction mixture was diluted with CH_2Cl_2 (10 mL). The organic layer was separated, washed with water, brine, dried (MgSO_4), and concentrated in vacuo. The residue was purified by preparative TLC (30% EtOAc in hexane) to give compounds **9** (109 mg, 77.2%) and **10** (16 mg, 15.8%) as a colorless oil, together with **8b** (6.1 mg, 6%) as colorless prisms.

9: IR (CHCl_3) 3404, 1744, 1151, 909, 826, 735 cm^{-1} ; ^1H NMR δ 1.14 (s, 9H), 1.21 (s, 9H), 1.74 (d, $J = 1.2$ Hz, 3H), 4.37 (s, 1H), 6.81 (s, 1H), 7.23 (d, $J = 7.6$ Hz, 1H), 7.33 (td, $J = 7.6$, 1.5 Hz, 1H), 7.47 (td, $J = 7.6$, 1.5 Hz, 1H), 8.03 (dd, $J = 7.6$, 1.5 Hz, 1H); MS m/z 353 (M^+), 296 ($\text{M}^+ - t\text{-Bu}$); HRMS calcd for $\text{C}_{18}\text{H}_{27}\text{NO}_4\text{S}$ 353.1661, found 353.1682.

10: IR (CHCl_3) 3418, 1215, 909, 759 cm^{-1} ; ^1H NMR δ 1.21 (s, 9H), 1.67 (d, $J = 1.0$ Hz, 3H), 4.65 (s, 2H), 6.80 (s, 1H), 7.27 (d, $J = 7.6$ Hz, 1H), 7.36 (td, $J = 7.6$, 1.5 Hz, 1H), 7.53 (td, $J = 7.6$, 1.5 Hz, 1H), 8.03 (dd, $J = 7.6$, 1.5 Hz, 1H); MS m/z 253 (M^+), 238 ($\text{M}^+ - \text{Me}$); HRMS calcd for $\text{C}_{13}\text{H}_{19}\text{NO}_2\text{S}$ 253.1136, found 253.1121.

(11*S*,12*R*,14*R*)-2-Fluoro-14-methyl-11-(methylethyl)spiro(2*H*,4*H*-benzo[*e*][1,2]thiazine-3,2'-cyclohexane) 1,1-dione (11*a*). A solution of **8g** (1.8 g, 5.86 mmol) in THF (60 mL) was treated with NaH (60% dispersion in mineral oil, 470 mg, 11.72 mmol) under N_2 at 0 °C, and the mixture was stirred at room temperature for 1 h. To the solution was introduced diluted perchloryl fluoride [FCIO_3 , generated from KClO_4 (8.12 g, 58.60 mmol) and FSO_3H (17 mL, 586 mmol)] for 3 h. The reaction was quenched by saturated aqueous NH_4Cl , and the mixture was extracted with EtOAc. The combined organic layers were washed with water and brine, dried (MgSO_4), and concentrated in vacuo. The residue was chromatographed (20% EtOAc in hexane) to give **11a** (1.54 g, 81%) as colorless prisms: mp 114–116 °C; $[\alpha]_{\text{D}}^{25} -48.7$ (c 0.47, CHCl_3); IR (KBr) 3027, 1363, 1184, 758 cm^{-1} ; ^1H NMR δ 0.77 (d, $J = 6.4$ Hz, 3H), 0.90 (d, $J = 6.6$ Hz, 3H), 0.98 (d, $J = 7.1$ Hz, 3H), 0.76–1.15 (m, 2H), 1.32–1.41 (m, 1H), 1.61–1.78 (m, 2H), 1.82–1.96 (m, 2H), 2.12–2.25 (m, 2H), 2.45 (dd, $J = 14.9$, 1.2 Hz, 1H), 3.74 (d, $J = 14.9$ Hz, 1H), 7.32 (d, $J = 7.6$ Hz, 1H), 7.49 (t, $J = 7.6$ Hz, 1H), 7.58 (t, $J = 7.6$ Hz, 1H), 7.93 (d, $J = 7.6$ Hz, 1H); ^{19}F NMR δ -52.9 (s); ^{13}C NMR δ 18.2 (18.3), 22.4, 22.8, 25.8, 26.3, 28.5, 35.6, 35.9 (36.0), 47.0 (47.2), 54.5, 73.5 (73.6), 126.6, 128.1, 129.9, 132.7, 133.6, 136.3; MS m/z 325 (M^+), 306 ($\text{M}^+ - \text{HF}$); HRMS calcd for $\text{C}_{17}\text{H}_{24}\text{FNO}_2\text{S}$ 325.1512, found 325.1536. Anal. Calcd for $\text{C}_{17}\text{H}_{24}\text{FNO}_2\text{S}$: C, 62.74; H, 7.43; N, 4.30. Found: C, 62.48; H, 7.71; N, 4.25.

(11*S*,12*S*,14*R*)-2-Fluoro-14-methyl-11-(methylethyl)spiro(2*H*,4*H*-benzo[*e*][1,2]thiazine-3,2'-cyclohexane) 1,1-Dione (11*b*). In the same way, **11b** was obtained from **8h** as colorless prisms (44%): mp 114–116 °C; $[\alpha]_{\text{D}}^{25} -4.6$ (c 1.00, CHCl_3); IR (KBr) 3027, 1455, 1361, 1180, 757 cm^{-1} ; ^1H NMR

δ 0.79 (d, $J = 6.1$ Hz, 3H), 0.87 (d, $J = 6.8$ Hz, 3H), 0.99 (d, $J = 6.8$ Hz, 3H), 1.01–1.16 (m, 1H), 1.32–1.54 (m, 4H), 1.70–1.85 (m, 3H), 2.46 (m, 1H), 3.14, 3.43 (ABq, $J = 14.9$ Hz, 2H), 7.32 (d, $J = 7.6$ Hz, 1H), 7.50 (t, $J = 7.6$ Hz, 1H), 7.56 (t, $J = 7.6$ Hz, 1H), 7.93 (d, $J = 7.6$ Hz, 1H); ^{19}F NMR δ -75.5 (s); ^{13}C NMR δ 19.0, 22.6, 23.1, 24.8, 25.5, 29.2 (29.3), 30.9, 34.6, 38.8 (39.1), 49.5, 76.9, 125.7, 128.0, 129.4, 133.8, 134.7, 135.8; MS m/z 325 (M^+), 306 ($\text{M}^+ - \text{HF}$); HRMS calcd for $\text{C}_{17}\text{H}_{24}\text{FNO}_2\text{S}$ 325.1512, found 325.1521. Anal. Calcd for $\text{C}_{17}\text{H}_{24}\text{FNO}_2\text{S}$: C, 62.74; H, 7.43; N, 4.30. Found: C, 62.79; H, 7.47; N, 4.24.

General Procedure for Asymmetric Fluorination of Ketone Enolates with 11*a* and 11*b*. To a stirred solution of ketone (0.15 mmol) in THF (2.0 mL) was added a 1.0 M solution of LiHMDS in THF (0.225 mL, 0.225 mmol) under nitrogen atmosphere at -78 °C. The mixture was stirred for 10 min at -78 °C, warmed to 0 °C, stirred for an additional 1 h, and cooled to -40 °C. A solution of **11** (58.5 mg, 0.18 mmol) in THF (2 mL) was added to the reaction mixture. After the reaction was complete, as indicated by TLC, the reaction mixture was quenched by addition of saturated aqueous NH_4Cl . EtOAc (10 mL) was added. The aqueous layer was extracted with EtOAc, the combined organic phases were washed with water and brine, dried (MgSO_4), and concentrated to give an oil that was purified by preparative TLC (Table 3).

(*S*)-2-Methyl-2-fluoro-1-indanone (12*a*): (76%) oil; 40% ee; $[\alpha]_{\text{D}}^{25} -21.6$ (c 0.47, CHCl_3). Its spectral properties were in agreement with literature values.^{4–6}

(*R*)-2-Methyl-2-fluoro-1-indanone (12*b*): (69%) oil; 13% ee; $[\alpha]_{\text{D}}^{25} +6.3$ (c 0.51, CHCl_3). **12b** exhibited the same spectral properties (IR, MS, ^1H NMR, and ^{19}F NMR) as **12a**.

(*S*)-2-Benzyl-2-fluoro-1-indanone (12*c*): (59%) oil; 54% ee; $[\alpha]_{\text{D}}^{25} -57.5$ (c 0.42, CHCl_3). Its spectral properties were in agreement with literature values.^{4–6}

(*R*)-2-Benzyl-2-fluoro-1-indanone (12*d*): (42%) oil; 24% ee; $[\alpha]_{\text{D}}^{25} +27.2$ (c 0.62, CHCl_3). **12d** exhibited the same spectral properties (IR, MS, ^1H NMR, and ^{19}F NMR) as **12c**.

(-)-2-*p*-Methoxybenzyl-2-fluoro-1-indanone (12*e*): (52%) oil; 51% ee; $[\alpha]_{\text{D}}^{25} -44.3$ (c 0.41, CHCl_3); IR (neat) 3018, 1726, 1610, 1513, 1250, 917, 836, 757 cm^{-1} ; ^{19}F NMR δ -154.8 (m); ^1H NMR δ 2.92 (dd, $J = 29.7$, 14.3 Hz, 1H), 3.15 (dd, $J = 22.8$, 17.3 Hz, 1H), 3.35 (m, 2H), 3.78 (s, 3H), 6.82 (d, $J = 8.6$ Hz, 2H), 7.18 (d, $J = 8.6$ Hz, 2H), 7.39 (dd, $J = 13.2$, 7.6 Hz, 2H), 7.61 (t, $J = 7.6$ Hz, 1H), 7.80 (d, $J = 7.6$ Hz, 1H); MS m/z 271 ($\text{M}^+ + 1$), 270 (M^+), 250 ($\text{M}^+ - \text{HF}$); HRMS calcd for $\text{C}_{17}\text{H}_{15}\text{FO}_2$ 270.1056, found 270.1051.

(-)-5,6-Dimethoxy-2-benzyl-2-fluoro-1-indanone (12*f*): (61%) oil; 33% ee; $[\alpha]_{\text{D}}^{25} -33.8$ (c 0.65, CHCl_3); IR (neat) 3021, 1710, 1593, 1501, 1283, 919, 866, 756 cm^{-1} ; ^1H NMR δ 2.89 (dd, $J = 29.8$, 14.1 Hz, 1H), 2.98 (dd, $J = 22.9$, 17.5 Hz, 1H), 3.23 (dd, $J = 17.5$, 12.0 Hz, 1H), 3.33 (t, $J = 13.5$ Hz, 1H), 3.84 (s, 3H), 3.87 (s, 3H), 6.68 (s, 1H), 7.13 (s, 1H), 7.20 (m, 5H); ^{19}F NMR δ -153.5 (m); MS m/z 301 ($\text{M}^+ + 1$), 300 (M^+), 280 ($\text{M}^+ - \text{HF}$); HRMS calcd for $\text{C}_{18}\text{H}_{17}\text{FO}_3$ 300.1162, found 300.1174.

(*S*)-2-Fluoro-2-methyl-1-tetralone (12*g*): (65%) oil; 70% ee; $[\alpha]_{\text{D}}^{25} -15.1$ (c 0.62, CHCl_3). Its spectral properties were in agreement with literature values.^{4–6}

(*S*)-2-Benzyl-2-fluoro-1-tetralone (12*h*): (61%) oil; 56% ee; $[\alpha]_{\text{D}}^{25} -28.2$ (c 0.49, CHCl_3). Its spectral properties were in agreement with literature values.^{4–6}

Acknowledgment. This work was supported by a Grant-in Aid for Scientific Research from the Ministry of Education, Science, Sports and Culture, Japan. We are also grateful to Dr. Bando Masahiko, Institute of Organic Chemistry, Otsuka Pharmaceutical Co., for his X-ray analysis of the absolute structure of compound **11a**.

Supporting Information Available: ORTEP diagram of **11a**, its details of crystallographic information, and ^1H NMR spectra for compounds **9**, **10**, and **12a,c,e–h**. This material is available free of charge via the Internet at <http://pubs.acs.org>.